Source-grounded facts extracted from Cullinan Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Cullinan Therapeutics, Inc. shareholders approved Advisory Vote on Executive Compensation at the 2026-06-16 meeting.
“The Company's stockholders approved the advisory vote on the compensation of the Company's named executive officers by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 48,536,734 1,092,209 7,057 4,126,430”
Cullinan Therapeutics, Inc. shareholders approved Ratification of Appointment of KPMG LLP as Independent Registered Public Accounting Firm at the 2026-06-16 meeting.
“The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2026 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 53,722,477 36,815 3,138 0”
Cullinan Therapeutics, Inc. shareholders approved Election of Class III Directors at the 2026-06-16 meeting.
“The Company's stockholders elected two Class III directors to the Company's Board of Directors for three-year terms or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Nadim Ahmed 37,519,241 12,116,759 4,126,430 Stephen Webster 36,963,086 12,672,914 4,126,430”
Cullinan Therapeutics, Inc. reported first quarter ended March 31, 2026 results: net income Net loss was $49.7 million for the first quarter of 2026.
“On May 7, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the three months ended March 31, 2026.”
Cullinan Therapeutics, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss attributable to Cullinan was $50.7 million for the fourth quarter of 2025, compared to $47.6 million for the sa.
“On March 10, 2026, Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the year ended December 31, 2025.”
Cullinan Therapeutics, Inc. terminated Exclusive Patent License Agreement with Massachusetts Institute of Technology (MIT) valued at termination effective February 18, 2026; return of licensed patent rights for CLN-617 (effective 2026-02-18).
“On November 18, 2025, in connection with its decision not to pursue further development of CLN-617, Cullinan Amber Corp. (the "Company"), a subsidiary of Cullinan Therapeutics, Inc. notified Massachusetts Institute of Technology ("MIT") of its decision to terminate the Exclusive Patent License Agreement, dated December 20, 2019 between the Company and MIT, as amended from time to time (the "License Agreement"), effective as of February 18, 2026.”
Cullinan Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss (before items attributable to noncontrolling interest) for the first quarter of 2024 was $37.3 million.
“Cullinan Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024.”
Thomas Ebeling resigned as Director at Cullinan Therapeutics, Inc..
“Thomas Ebeling notified the Board of his intention to serve out his current term and resign as a director effective as of June 26, 2024.”
David Meek was appointed as Class I Director at Cullinan Therapeutics, Inc..
“the Board of Directors (the “Board”) of the Company appointed David Meek as a Class I director, effective May 15, 2024.”
Mary Kay Fenton was appointed as Chief Financial Officer at Cullinan Therapeutics, Inc..
“On April 29, 2024, Cullinan Therapeutics, Inc. (the “Company”) announced the hiring and appointment of Mary Kay Fenton as the Company’s Chief Financial Officer, effective immediately.”
Cullinan Therapeutics, Inc.: Amended and restated bylaws solely to reflect the name change (effective 2024-04-15).
“the Board also approved an amendment and restatement of the Company’s Second Amended and Restated Bylaws solely to reflect the Name Change (as amended and restated, the “ Third Amended and Restated Bylaws ”) effective as of April 15, 2024.”
Cullinan Therapeutics, Inc.: Amended certificate of incorporation to change company name from Cullinan Oncology, Inc. to Cullinan Therapeutics, Inc (effective 2024-04-15).
“Effective as of 9:47 A.M., Eastern Time on April 15, 2024, the Company amended its Second Amended and Restated Certificate of Incorporation, as amended (the “ Certificate of Incorporation ”), to effect a change of the Company’s name from “Cullinan Oncology, Inc.” to “Cullinan Therapeutics, Inc.” (the “ Name Change ”).”
Cullinan Therapeutics, Inc. entered into Stock Purchase Agreement with certain institutional accredited investors valued at $280M gross proceeds for sale of 14,421,070 shares at $19.00/share and 315,790 pre-funded warrants a (effective 2024-04-15).
“On April 15, 2024, Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc.) (the “ Company ”) entered into a Stock Purchase Agreement (the “ Purchase Agreement ”) for a private placement (the “ Private Placement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”).”
Cullinan Therapeutics, Inc. reported financial results for the quarter and year ended December 31, 2023.
“On March 14, 2024, Cullinan Oncology, Inc. announced its financial results for the quarter and year ended December 31, 2023.”
Cullinan Therapeutics, Inc. updated its as of December 31, 2023 guidance (reaffirmed).
“As of December 31, 2023, the Company's unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023.”
Cullinan Therapeutics, Inc. updated its quarter ended December 31, 2023 guidance (reaffirmed).
“As of December 31, 2023, Cullinan Oncology, Inc.’s (the “Company’s”) unaudited cash, cash equivalents, investments, and interest receivable totaled $468.3 million. Consistent with prior guidance, the Company expects its cash resources to provide runway into the second half of 2026 based on its current operating plan. The Company has not yet completed its quarter-end financial close process for the quarter ended December 31, 2023. This estimate of the Company’s cash, cash equivalents, investments, and interest receivable as of December 31, 2023 is preliminary, has not been audited and is subject to change upon completion of the Company’s financial statement closing procedures.”
Cullinan Therapeutics, Inc. updated its third quarter ended September 30, 2023 guidance (reaffirmed).
“Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2023.”
Cullinan Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
“Cullinan Oncology, Inc. (Nasdaq: CGEM; “Cullinan”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today reported on recent and upcoming business highlights and announced its financial results for the second quarter ended June 30, 2023.”
Cullinan Therapeutics, Inc. shareholders approved Ratification of appointment of KPMG LLP as independent registered accounting firm for fiscal year ending December 31, 2023 at the 2023-06-08 meeting.
“Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered accounting firm for the fiscal year ending December 31, 2023 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 34,563,271 272,925 171 0”
Cullinan Therapeutics, Inc. shareholders approved Election of two Class III directors to serve for three-year terms at the 2023-06-08 meeting.
“Proposal One — Election of Directors The Company’s stockholders elected two Class III directors to the Company’s Board of Directors for three-year terms or until his successor has been duly elected and qualified, or until his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Nadim Ahmed 28,651,746 346,553 5,838,068 Stephen Webster 21,598,415 7,399,884 5,838,068”
Patrick Baeuerle changed role as Co-Founder, Chief Scientific Advisor at Cullinan Therapeutics, Inc..
“Upon mutual agreement between Patrick Baeuerle and Cullinan Oncology, Inc. (the “Company”), Dr. Baeuerle will transition from Chief Scientific Officer of the Company to Co-Founder, Chief Scientific Advisor of the Company effective June 8, 2023.”
Cullinan Therapeutics, Inc. reported financial results for the quarter ended March 31, 2023.
“On May 11, 2023, Cullinan Oncology, Inc. announced its financial results for the quarter ended March 31, 2023.”
Cullinan Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2022 results: net income 27.1 million.
“Net loss (before items attributable to noncontrolling interest) for the fourth quarter of 2022 was $27.1 million, compared with net loss of $24.9 million for the third quarter of 2022.”
Cullinan Therapeutics, Inc. entered into License Agreement with Harbour BioMed US Inc. valued at $25 million upfront license fee (effective 2023-02-13).
“On February 13, 2023, Cullinan Oncology, Inc. (the "Company") and Harbour BioMed US Inc. ("Harbour") entered into a License and Collaboration Agreement (the "License Agreement"), pursuant to which Harbour granted to the Company an exclusive license for the development, manufacturing and commercialization of HBM7008 (CLN-418) in the U.S.”
Cullinan Therapeutics, Inc. reported financial results for the quarter ended September 30, 2022.
“On November 14, 2022, Cullinan Oncology, Inc. announced its financial results for the quarter ended September 30, 2022.”
Ansbert Gadicke resigned as director at Cullinan Therapeutics, Inc..
“Ansbert Gadicke, M.D. notified the Board of his intention to resign as a director effective as of November 1, 2022.”
David P. Ryan was appointed as Class II director at Cullinan Therapeutics, Inc..
“appointed David P. Ryan, M.D. as a Class II director, effective immediately.”
Jeffrey Jones was appointed as Chief Medical Officer at Cullinan Therapeutics, Inc..
“On February 28, 2022, Cullinan Oncology, Inc. (the “Company”) announced the hiring and appointment of Jeffrey Jones, M.D., MPH, MBA as the Company’s Chief Medical Officer, effective immediately.”
Morana Jovan-Embiricos departed as Director at Cullinan Therapeutics, Inc..
“On December 27, 2021, Morana Jovan-Embiricos notified the Board of Directors of Cullinan Oncology, Inc. (the “Company”) of her intention to resign as a director effective as of December 31, 2021”
Nadim Ahmed was appointed as Class III Director at Cullinan Therapeutics, Inc..
“the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021”
Nadim Ahmed was appointed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
“the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021”
Owen Hughes departed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
“Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.